CBS News (June 5)
Following the close of the Bayer Monsanto merger, a “toxic corporate name” will be retired. Soon after the $60 billion all-cash deal closes on Wednesday, the Monsanto name will be retired. Bayer “wanted the pesticide producer but seemingly not all the associated baggage that comes with the name.” The decision shows “how anti-Monsanto demonstrations over the years have succeeded in molding the public’s view of the company.”
Wall Street Journal (September 14)
“For Monsanto owners, selling to Bayer provides a premium of 44%.” With relatively little overlap between the companies, antitrust issues should be less likely to threaten the merger. Moreover, “the deal seems to make strategic sense, as Bayer combines its pesticides franchise with a leader in seeds and biotechnology. Bayer is also known for health care, which will generate about half of the combined company’s sales. Crop sciences will contribute roughly the other half.”
Tags: Antitrust, Bayer, Biotechnology, Crop sciences, Health care, Merger, Monsanto, Overlap, Pesticides, Premium, Seeds
